2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 901

Rate of Serum Uric Acid (SUA) Assessment in Gout Patients Treated with Urate-Lowering Therapy: Treating to Target?
Abstract Number: 1051

Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Abstract Number: 2010

Reaching out to Physical Therapists: Results of a Survey on Physical Therapists Preferences for Learning about Evidence-Based Community Programs
Abstract Number: 484

Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy
Abstract Number: 2121

Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Abstract Number: 517

Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results
Abstract Number: 102

Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Abstract Number: 956

Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Abstract Number: 2516

Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients
Abstract Number: 104

Reasons for Leaving an Academic Career in Research Among Rheumatologists in the United States
Abstract Number: 2385

Reasons for Non-Vaccination in Rheumatoid Arthritis and Spondyloarthritis Patients
Abstract Number: 2572

Recognition of Spondyloarthritis By General Practitioners in Daily Practice and the Effect of Education on This; A Study with Standardized Patients
Abstract Number: 1235

Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease
Abstract Number: 1417

Red Cell Distribution Width: A Measure for Cardiovascular Risk in Rheumatoid Arthritis Patients?
Abstract Number: 2210

Redefining Dermatomyositis: Description of New Diagnostic Criteria That Differentiate Pure Dermatomyositis from Overlap Myositis with Dermatomyositis Features

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].